{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:20:31Z","timestamp":1775042431141,"version":"3.50.1"},"reference-count":67,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T00:00:00Z","timestamp":1323129600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Prospectively planned pooled analysis evaluating efficacy and tolerability of acute quetiapine XR monotherapy in generalised anxiety disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from three 10\u2010week, randomised, double\u2010blind, placebo\u2010controlled studies of similar design were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Week 8, Hamilton Anxiety Rating Scale (HAM\u2010A) total score significantly improved with quetiapine XR: least squares means change \u221213.31, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 (50\u2009mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u2009452), \u221214.39, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 (150\u2009mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u2009673) and \u221212.50, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 (300\u2009mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u2009444) versus \u221211.30 placebo; significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>n<\/jats:italic>\u2009=\u2009665) improvements versus placebo were observed with each dose at Week 1. Significant improvements versus placebo at Week 8 are as follows: HAM\u2010A psychic symptom subscale, Montgomery\u2010\u00c5sberg Depression Rating Scale total, Pittsburgh Sleep Quality Index global scores for all quetiapine XR doses; HAM\u2010A response and remission rates, HAM\u2010A somatic symptom subscale score, Clinical Global Impression\u2010Severity of Illness total score, % patients with Clinical Global Impression\u2010Improvement score \u22642 with quetiapine XR 50 and 150\u2009mg\/day; and Quality of Life Enjoyment and Satisfaction Questionnaire short form % maximum total score with quetiapine XR 150\u2009mg\/day. In the quetiapine XR 50, 150 and 300\u2009mg\/day and placebo groups, 13.2%, 16.5%, 24.0% and 5.4% of patients discontinued because of an adverse event, and 1.9%, 1.4%, 3.7% and 1.8% of patients experienced clinically significant changes in glucose. The most common adverse events with quetiapine XR included dry mouth, somnolence, sedation and constipation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Quetiapine XR monotherapy reduced the symptoms of generalised anxiety disorder, with improvement from Week 1. Adverse events were consistent with the known tolerability profile of quetiapine. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1256","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T06:42:52Z","timestamp":1323153772000},"page":"614-628","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8\u2010week placebo\u2010controlled studies"],"prefix":"10.1002","volume":"26","author":[{"given":"Dan J.","family":"Stein","sequence":"first","affiliation":[{"name":"Department of Psychiatry University of Cape Town  Cape Town South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borwin","family":"Bandelow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy University of Goettingen  Goettingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Merideth","sequence":"additional","affiliation":[{"name":"Affiliated Research Institute Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Olausson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&amp;D  Sodertalje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Szamosi","sequence":"additional","affiliation":[{"name":"AstraZeneca R&amp;D  Sodertalje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&amp;D  Sodertalje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900006945"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105059253"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004870"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990423"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199803003-00009"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04629"},{"key":"e_1_2_7_12_1","first-page":"1362","article-title":"Generalized anxiety disorder and health care use","volume":"51","author":"Belanger L","year":"2005","journal-title":"Can Fam Physician"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.06.004"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.06.031"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.6.1179"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"issue":"2","key":"e_1_2_7_18_1","first-page":"1S","article-title":"Management of anxiety disorders","volume":"51","author":"Canadian Psychiatric Association","year":"2006","journal-title":"Can J Psychiatry"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900026651"},{"issue":"5","key":"e_1_2_7_20_1","first-page":"7","article-title":"Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound","volume":"65","author":"Chouinard G","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.1.50"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04592"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0805"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000015"},{"key":"e_1_2_7_25_1","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott J","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f0f0d7"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v03n0105"},{"key":"e_1_2_7_28_1","first-page":"11","article-title":"Compliance with antipsychotic drug treatment: influence of side effects","volume":"382","author":"Fleischhacker WW","year":"1994","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056527"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.3.283"},{"issue":"2","key":"e_1_2_7_31_1","first-page":"24","article-title":"Treating generalized anxiety disorder","volume":"64","author":"Gorman JM","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"e_1_2_7_32_1","first-page":"CD006815","article-title":"Hydroxyzine for generalised anxiety disorder","volume":"8","author":"Guaiana G","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_33_1","first-page":"218","volume-title":"ECDEU Assessment Manual For Psychopharmacology Publication","author":"Guy W","year":"1976"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20249"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107076996"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0712"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301646"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0603"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923020-00002"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833e34d9"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/00926230500232909"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"e_1_2_7_44_1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1176\/ajp.156.12.1915","article-title":"Impairment in pure and comorbid generalized anxiety disorder and major depression at 12\u2009months in two national surveys","volume":"156","author":"Kessler RC","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318224864d"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.010"},{"key":"e_1_2_7_47_1","first-page":"239","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD)","volume":"10","author":"Magi K","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970802503086"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0bo13e32834d9f49"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.4.363"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0511"},{"key":"e_1_2_7_53_1","unstructured":"National Institute for Health and Clinical Excellence.2011.Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. Available athttp:\/\/www.nice.org.uk\/nicemedia\/live\/13314\/52599\/52599.pdf."},{"issue":"19","key":"e_1_2_7_54_1","first-page":"5","article-title":"Dissolving the burden of generalized anxiety disorder","volume":"62","author":"Ninan PT","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(08)70352-3"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(10)71429-2"},{"issue":"19","key":"e_1_2_7_57_1","first-page":"20","article-title":"Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission","volume":"62","author":"Pollack MH","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0508"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1614.2004.01382.x"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833a4d71"},{"issue":"20","key":"e_1_2_7_61_1","first-page":"22","article-title":"The Mini\u2010International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/10401230590932335"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.10.007"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.853"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020307"},{"issue":"8","key":"e_1_2_7_68_1","first-page":"24","article-title":"Generalized anxiety and depression in primary care: prevalence, recognition, and management","volume":"63","author":"Wittchen HU","year":"2002","journal-title":"J Clin Psychiatry"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1256","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T06:12:47Z","timestamp":1700547167000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1002\/hup.1256"],"URL":"https:\/\/doi.org\/10.1002\/hup.1256","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}